Around the end of every year, the media reports on pregnancy and women who give birth on the last and first days of the new year. They tell their stories, the names of their babies and the cities where they were born. While 2024 was coming to an end, gynecologists and other researchers finalized their publications to improve the health of women and their babies. The formation of the placenta or the study of preeclampsia are some of the first and last stories that greet and say goodbye to 2024. Those of 2025 will be born soon. Read More
The aberrant immune response against self-antigens occurring in autoimmune diseases involves dysregulation of members of intracellular signal transduction pathways such as interleukin-2-inducible T cell kinase (ITK) and Janus kinase (JAK). Aclaris Therapeutics Inc. has detailed the characterization of ATI-2138, a dual ITK/JAK3 covalent inhibitor. Read More
Amylyx Pharmaceuticals Inc. and Gubra A/S have established a collaboration for the development of a novel long-acting GLP-1 receptor antagonist. Read More
Azole derivatives have been used as antifungal drugs in clinical practice for many years. However, limitations such as drug-drug interactions, severe adverse events from prolonged use, and high resistance prevalence highlight the urgent need for new therapeutic options to treat the rising number of invasive fungal infections. Read More
Novel vaccines that can effectively target both coronaviruses and influenza viruses would be desirable to counteract the significant health burden these respiratory pathogens pose. Read More
Deficiencies in the SLC6A1 gene, encoding the γ-aminobutyric acid transporter GAT-1, are associated with infantile encephalopathy with intellectual disability. Like other neurodevelopmental disorders, SLC6A1-related disorders lack effective treatments; therefore, gene therapy using viral vectors has been proposed as a potential therapeutic strategy. Read More
Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful for the treatment of cancer. Read More
Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker. Read More
Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition following SARS-CoV-2 infection associated with intestinal manifestations. The most common clinical features include fever, abdominal pain, rash, myocardial dysfunction and elevated inflammatory biomarkers. Read More
Unogen Biotech Ltd. has identified triple inhibitors of EGFR (HER1; erbB1), ALK tyrosine kinase receptor and hepatocyte growth factor receptor (HGFR; MET) reported to be useful for the treatment of (non-small-cell) lung cancer. Read More
Nico Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease and nonalcoholic fatty liver disease (metabolic dysfunction-associated steatotic liver disease [MASLD]). Read More
Lario Therapeutics Ltd. has divulged voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) blockers reported to be useful for the treatment of neurodegeneration, neurodevelopmental disorders, epilepsy, Parkinson’s disease, endocrine disorders, cerebral vasospasm, pain and epileptic encephalopathy. Read More
